Advaxis announced today that it will be a participant in the Canaccord Genuity Orphan Drug One-on-One Day. The event will be taking place at the Omni Berkshire Place in New York City on Monday, February 24, 2014.
At the event Advaxis will be connecting with key investors in the biotechnology sector who focus on companies that are developing drugs with an Orphan Drug Designation. This designation is given to drugs that are intended to treat diseases or conditions that afflict fewer than 200,000 people within the United States. With it, a company may enjoy clinical protocol assistance with the FDA, as well as federal grants, tax credits, and even a seven-year market exclusivity period.
Advaxis’ lead drug candidate, ADXS-HPV has received an Orphan Drug Designation from the US FDA Office of Orphan Products Development. The drug candidate has received this designation for treatment of HPV-associated anal cancer and head and neck cancer.
Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis’ immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.
For more information, visit: www.advaxis.com
Let us hear your thoughts:
